Feature | Contrast Media | June 04, 2015

First U.S. Lumason Echocardiography Imaging Procedure Performed

Contrast agent indicated to opacify left ventricular chamber in suboptimal echocardiograms

Bracco, Lumason, first U.S. echocardiography procedure, Morristown

June 4, 2015 - Bracco Imaging announced that the first echocardiography imaging procedure with Lumason was performed in May at Morristown Medical Center, part of the Atlantic Health System, in New Jersey. This is the first administration after the development of the agent (sulfur hexafluoride lipid-type A microspheres) in the United States and approval by the U.S. Food and Drug Administration. The announcement was made through Bracco Imaging's affiliate Bracco Diagnostics Inc.

 "We're thrilled to be the first medical center to use Lumason in adults with suboptimal echocardiograms," said Linda Gillam, M.D., MPH, FASE, chair of the Gagnon Cardiovascular Institute at Morristown Medical Center. "Now we have an additional option when performing contrast enhanced ultrasound."

Lumason, internationally known as SonoVue in 40 countries, is an ultrasound contrast agent made up of gas-filled microbubbles (or microspheres) that reflect the sound waves to enhance the image.

Lumason has been approved by the FDA for use in adults with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

The agent is supplied as a three-part kit. Each kit contains a Lumason vial containing 25 mg of lipid-type A lyophilized powder and 60.7 mg sulfur hexafluoride headspace, a prefilled syringe containing 5 mL of sodium chloride 0.9 percent injection, USP (Diluent), and a Mini-Spike.

For more information: www.braccoimaging.com

Related Content

The Revolution Apex intelligent computed tomography (CT) scanner

The Revolution Apex intelligent computed tomography (CT) scanner. Image courtesy of GE Healthcare.

News | RSNA | October 18, 2019
At the 2019 annual meeting of the Radiological Society of North America (RSNA 2019), Dec. 1-6 in Chicago, GE Healthcare...
Philips Partners With PURE on Tele-Ultrasound Program for Physicians in Rwanda
News | Ultrasound Imaging | October 09, 2019
Philips and non-profit organization PURE (Point-of-care Ultrasound in Resource-limited Environments) highlighted a tele...
Samsung to Unveil Hera I10 Ultrasound at SDMS 2019
Technology | Ultrasound Women's Health | September 28, 2019
NeuroLogica, a subsidiary of Samsung Electronics Co. Ltd., announced that the Samsung Hera I10 ultrasound system has...
Fujifilm Sonosite Partnering With Artificial Intelligence Incubator to Improve Ultrasound Image Interpretation
News | Ultrasound Imaging | September 23, 2019
Fujifilm SonoSite Inc. and the Allen Institute of Artificial Intelligence (AI2) Incubator, builder of AI-first startups...
Bayer Introduces Medrad Stellant Flex CT Injection System
Technology | Contrast Media Injectors | September 11, 2019
Bayer announced the introduction of the Medrad Stellant Flex computed tomography (CT) injection system. Stellant Flex...
ASNC Announces Multisocietal Cardiac Amyloidosis Imaging Consensus
News | Cardiac Imaging | September 09, 2019
September 9, 2019 — The American Society of Nuclear Cardiology (ASNC) published a new expert consensus document along
Characteristics nephrologists associate with renal high-risk patients. (n=13)

Characteristics nephrologists associate with renal high-risk patients. (n=13)

Feature | Contrast Media | September 05, 2019
The global rise in chronic disease has significantly increased demand for diagnostic imaging procedures, and in turn,
Medical Imaging Rates Continue to Rise Despite Push to Reduce Their Use
News | Radiology Imaging | September 03, 2019
Despite a broad campaign among physician groups to reduce the amount of medical imaging, use rates of various scans...
News | Contrast Media | September 03, 2019
Researchers in South Korea have found that patients with family and personal history of allergic reactions to contrast...